TRILEPTAL monotherapy achieved greater control in adult patients still experiencing partial seizures on up to 2 antiepileptic drugs (AEDs) Significant reduction in frequency of partial seizures following conversion to TRILEPTAL monotherapy1,2

Adult Efficacy Pediatric Efficacy First-line Use TRILEPTAL vs CBZ

Prior to being converted to TRILEPTAL (2400 mg/day), patients were experiencing a median of 10.5 seizures per 28 days while taking therapeutic doses of up to 2 AEDs, including1 —Carbamazepine (54%) —Phenytoin (20%) —Valproate (15%) —Lamotrigine (12%) —Gabapentin (10%)

Long-term, open-label extension:

Data from 51% of patients who remained on TRILEPTAL monotherapy for up to 2 years³


Two-year, open-label extension phase of a multicenter, randomized, double-blind, dose-controlled, monotherapy substitution trial of 87 patients aged 11 to 66 years.³

In an open-label extension phase of patients converted from up to 2 AEDs, all patients (N=76) either continued on TRILEPTAL monotherapy or received polytherapy as clinically needed3 — 51% of patients (n=39) remained on TRILEPTAL monotherapy — 49% of patients (n=37) received polytherapy (not included in graph above)

NEXT: See data on breakthrough partial seizures

1.		Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2.		Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology. 2000;54:2245-2251.
3.		Minecan D, Beydoun A, Sachdeo R, D'Souza J. Safety and efficacy of oxcarbazepine after 2 years' treatment in patients with inadequately controlled partial-onset seizures. Poster presented at: American Epilepsy Society 56th Annual Meeting; December 6-11, 2002; Seattle, Wa.